Y-Mabs Therapeutics Inc (YMAB)

$YMAB https://prismmarketview.com/y-mabs-highlights-radiopharmaceutical-progress-and-pipeline-expansion-at-rd-update/

$YMAB Y-mAbs Highlights Ongoing Phase 1 Trial Of GD2-SADA PRIT With 177Lu-DOTA At ANR 2025 In Washington, D.C.

HC Wainwright & Co. has updated their rating for Y-mAbs Therapeutics ( $YMAB ) to Buy with a price target of 11.

$YMAB when will this nightmare end 🤨

Oppenheimer updates rating for Y-mAbs Therapeutics ( $YMAB ) to Outperform, target set at 21 → 20.

$YMAB Y-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $82.49M Cash and cash equivalents are anticipated to be sufficient to fund operations as currently planned into 2027.

$YMAB Y-mAbs Therapeutics reports Q1 EPS (12c), consensus (20c) Reports Q1 revenue $20.9M, consensus $19.61M. As of March 31, 2025, Y-mAbs had approximately $60.3M in cash and cash equivalents which, together with anticipated DANYELZA product revenues, is expected to support operations as currently planned into 2027. "We closed Q1 2025 demonstrating solid DANYELZA net product revenue, advancement of our novel SADA PRIT platform and programs, and prudent operational spending," said CEO Michael Rossi. "We were pleased to have dosed the first patient in our Trial 1201 where our innovative approach to pretargeted radioimmunotherapy has the potential to improve outcomes for patients in the high-risk population with relapsed/refractory non-Hodgkin Lymphoma. Starting in the first quarter of 2025, we began operating as two separate business units, DANYELZA and Radiopharmaceuticals, and in doing so, our reporting highlights DANYELZA's segment profit in addition to the resource investments we are making to advance our radioimmunotherapy platform. We look forward to sharing updates on our radiopharmaceutical business strategy, including Part A clinical data from Trial 1001, new optimization data, and new planned target programs and anticipated timelines, during our virtual Radiopharmaceutical R&D update on May 28th."

$YMAB Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

$YMAB Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA Y-mAbs Therapeutics announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at the 2025 American Association of Cancer Research, AACR, Annual Meeting being held on April 25-30, 2025 in Chicago, IL. The poster titled "Preclinical and translational pharmacokinetic modeling of the self-assembling and disassembling, SADA, bispecific fusion protein CD38-SADA for first-in-human pretargeted radioimmunotherapy" characterizes the plasma concentrations of CD38-SADA in animal models over time and a range of doses. Utilizing in vitro binding kinetic parameters and PK data generated from three studies in mice, the study characterized the concentration- and time-dependent equilibrium between CD38-SADA tetramers and monomers.